Pre-Stem Cell Transplant Treatment Regimen for AML, MDS - NCI
Price: $ 763.99
4.9(263)
A Cancer Currents blog on a study suggesting that an intensive preparatory regimen should be used for younger patients with AML undergoing a stem cell transplant.
Pre-Stem Cell Transplant Treatment Regimen for AML, MDS - NCI
IJMS, Free Full-Text
Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study - The Lancet Haematology
Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis - Transplantation and Cellular
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome - ScienceDirect
